• B2B (Clinics): Selling the analysis system to neurology and research-oriented clinics via a SaaS model with recurring yearly licenses. • B2B2C (Patients): Distributing NUSHU shoes directly to patients through an established physical therapist (PT) network and partner programs. • Data Monetization: Partnering with Big Pharma and MedTech companies to monetize pathology-specific baseline data for clinical trials. • US Expansion: Utilizing a 3-pillar approach including self-payers, DME reimbursement path, and a dedicated distributor for the Veterans Affairs (VA) network, with an FSS contract expected in Q2 2026. • Reimbursement: Full reimbursement is already established in Norway (NAV), with DME reimbursement expected in the USA by 2027.
Magnes transforms neuro-care from episodic clinic visits to continuous AI-driven intervention. Our NUSHU footwear delivers clinical-grade gait analysis and real-time vibrotactile biofeedback, actively recalibrating mobility for Parkinson’s patients during daily life.